Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 1, 2014

Primary Completion Date

December 1, 2024

Study Completion Date

December 12, 2025

Conditions
Carcinoma, Non-Small Cell LungEGFR Gene Mutation
Interventions
DRUG

Gemcitabine platinum combined with erlotinib

patients will received a 28 days gemcitabine platinum combined with erlotinib scheme, after 4 cycles combined chemotherapy, patients will receive erlotinib for maintain treatment until progression disease.Gemcitabine for day 1 and day 8, 1250mg/m2. Platinum for day 1, 75mg/m2. Erlotinib for day 9-21 during combined chemotherapy, 150mg/day, then erlotinib should be used daily until patients develop progression disease.

Trial Locations (1)

Unknown

RECRUITING

Hunan Province Tumor Hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER